Free Trial

XOMA Q3 2023 Earnings Report

XOMA logo
$26.76 -0.53 (-1.94%)
As of 01/17/2025 04:00 PM Eastern

XOMA EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

XOMA Revenue Results

Actual Revenue
$0.83 million
Expected Revenue
$1.47 million
Beat/Miss
Missed by -$640.00 thousand
YoY Revenue Growth
N/A

XOMA Announcement Details

Quarter
Q3 2023
Time
N/A

XOMA Earnings Headlines

StockNews.com Upgrades XOMA (NASDAQ:XOMA) to Hold
I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Contrasting XOMA (NASDAQ:XOMA) and Oragenics (NYSE:OGEN)
XOMA (NASDAQ:XOMA) Stock Rating Lowered by StockNews.com
See More XOMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA and other key companies, straight to your email.

About XOMA

XOMA (NASDAQ:XOMA) operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Profile

More Earnings Resources from MarketBeat